Spyre Therapeutics Reports Q3 2026 Results and Positive SPY003 Trial Data
Spyre Therapeutics reported third-quarter 2026 financial results and announced positive topline induction data for SPY003 from Part A of its Phase 2 SKYLINE trial.
Story updates
09:03:41 PM UTC
SquawkNews
Spyre Therapeutics reported a third-quarter 2026 net loss of $96.1 million, compared with a net loss of $11.2 million a year earlier. The clinical-stage biotechnology company ended September with $1.07 billion in cash, cash equivalents and marketable securities, and reported pro forma cash of appro…
09:04:11 PM UTC
SquawkNews
SPYRE THERAPEUTICS INC Q3 PRETAX PROFIT USD -96.121 MILLION VS. IBES ESTIMATE USD -82.6 MILLION
09:09:56 PM UTC
SquawkNews
Spyre reported Q3 2026 net loss of $96.1M versus $11.2M in Q3 2025. Pro forma cash was $1,467.9M at September 30, 2026, with expected runway into H2 2029; SPY003 showed positive topline induction data in Phase 2.Material DetailsContext by AI AnalystSpyre is a clinical-stage biotech in an active Pha…
09:14:23 PM UTC
SquawkNews
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…